Effects of high-to-mega-dose synthetic corticosteroids on multiple sclerosis patients with special reference to cerebrospinal fluid antibodies to myelin basic protein.
Warren
K G
KG
Multiple Sclerosis Patient Care and Research Clinic, University of Alberta, Edmonton, Canada.
Catz
I
I
Carroll
D J
DJ
D000906:Antibodies / Q000134:cerebrospinal fluid*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000276:immunology; D004676:Myelin Basic Protein / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use*
D000906:Antibodies; D004676:Myelin Basic Protein; D008776:Methylprednisolone Hemisuccinate; D011241:Prednisone; D008775:Methylprednisolone